Zoetis Inc.

ZTS Healthcare Drug Manufacturers Specialty & Generic

Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024.

Revenue
−0.24%
EPS
+2.48%
Free cash flow
+17.4%
Total debt
+37.5%

Quarter to June 2026, against a year earlier

80.26 1.85 −2.25%
Market cap
$33.9B
P/E
13.4×
Fwd P/E
14.2×
Dividend yield
2.59%
F-score
7/9
Altman Z
5.73
Beneish M
−2.45
Dividend safety
88/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

49.47% 65.31% 67.75% 64.91%
Piotroski F-Score
6 7 8 6
ROA
17.82% 17.98% 18.27% 17.84%
ROIC
19.89% 20.99% 20.22% 19.60%
Return on Tangible Assets
31.40% 32.23% 32.83% 32.75%
Average Days of Receivables
59.91 54.32 57.67 60.20
Free Cash Flow per Share
5.06 5.15 5.32 5.57
Free Cash Flow
2,240.00 2,283.00 2,247.00 2,327.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 25 Oct 2026